Press release
Metachromatic leukodystrophy treatment market 2025: Industry Developments, Future Growth, Share & Industry Insights | ArmaGen, Inc., GlaxoSmithKline plc, Takeda Pharmaceutical, Orchard Therapeutics plc, Magenta Therapeutics
Metachromatic leukodystrophy treatment market - DataM Intelligence
Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/metachromatic-leukodystrophy-treatment-market?sg
Industry Recent Developments 2025:
✅ (03 Feb 2025) - Orchard Therapeutics announced multiple 2025 data presentations (including long-term HSC gene-therapy data) and received the WORLD Symposium 2025 New Treatment Award for LenmeldyTM (recognition + scientific visibility during 2025 conference season).
✅ (12 Feb 2025) - Orchard (Kyowa Kirin) appointed Robin Kenselaar as Chief Commercial Officer and confirmed that first U.S. patients are being treated with LenmeldyTM in a commercial setting, signalling an active U.S. commercial roll-out in early 2025.
✅ (28 Feb 2025) - Spain (Interministerial Commission for the Pricing of Medicines) reached a reimbursement agreement for Libmeldy®/Lenmeldy, enabling reimbursed access for eligible early-onset MLD patients in the Spanish National Health System.
✅ (03 Feb 2025 - ongoing through 2025) - Multiple commercial / access activities across Europe continued in 2025 (qualification of additional treatment centres, country-level negotiations and managed-access pathways for Libmeldy), reflecting a phased European roll-out during 2025.
✅ (13 May 2025) - A major long-term outcomes publication for the HSC gene-therapy (Lenmeldy / atidarsagene autotemcel) appeared (NEJM / company announced publication), strengthening the evidence used in payer negotiations and HTA discussions through 2025.
✅ (Early 2025 - commercial launch activity) - Orchard / Kyowa Kirin continued to activate and qualify U.S. treatment centres (multiple sites planned/being qualified in 2024-2025) and reported commercial infusions in early 2025, marking the transition from regulatory approval to routine commercial delivery.
✅ (2025 - manufacturing & supply updates) - CDMO and manufacturing partners remained active in 2025 for commercial supply scale-up (AGC Biologics and Orchard manufacturing partnerships noted in company updates), supporting ongoing commercialisation in 2025.
✅ (M&A context - background relevant to 2025 activity) - (24 Jan 2024) Kyowa Kirin completed the acquisition of Orchard Therapeutics, a strategic deal that continued to shape Orchard/Kyowa's 2025 commercial and development activity for Lenmeldy/Libmeldy (this remains the principal M&A event affecting the MLD field into 2025).
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/metachromatic-leukodystrophy-treatment-market?sg
Key market growth drivers:
✅ Gene-therapy approvals and clinical progress - first gene therapy approvals for MLD (atidarsagene autotemcel / Lenmeldy / arsa-cel) have converted a previously purely palliative market into a market for potentially disease-modifying/curative single-administration products. This is the single biggest near-term market accelerator. (FDA approval: March 18, 2024).
✅ Improved diagnosis & newborn screening expansion - wider use of NGS and newborn screening programs increases case identification (earlier diagnosis → eligibility for early/curative therapies), expanding the addressable patient population.
✅ Orphan incentives / favorable regulatory pathways - orphan drug designations, accelerated/review pathways and rare-disease reimbursement mechanisms make high R&D investment and premium pricing more commercially viable.
✅ R&D and pipeline investment (lentiviral, AAV, HSCT + gene therapies) - active pipelines and positive long-term outcomes data raise commercial expectations and payer negotiation activity. (recent academic/NEJM outcomes papers support meaningful clinical benefit vs historical controls).
✅ Advocacy, payer negotiation models & outcome data - patient groups plus emerging long-term effectiveness data are accelerating coverage discussions and innovative payment models for one-time gene therapies.
Regional share:
➠ North America (largest share): largest regional market, typically reported as holding the biggest share (estimates often place North America >35-55% of the global rare/MLD therapy market), driven by early regulatory approvals, advanced newborn screening, high gene-therapy adoption and stronger payer willingness to reimburse in some cases.
➠ Europe: significant share (often cited as the 2nd largest region). Europe's market is driven by earlier regulatory approvals in certain countries (e.g., Libmeldy/arsa-cel rollout in EU earlier than US in some pathways), national newborn-screening pilots, and centralized reimbursement negotiations.
➠ Asia-Pacific: fastest growth prospects (higher CAGR expectations) as diagnosis rates improve, newborn screening expands, and gene-therapy capacity / access programs scale - but current share is smaller than NA/EU in 2024.
Segments Covered in the Metachromatic leukodystrophy Treatment Market:
By Type (Late-Infantile MLD, Juvenile MLD, Adult MLD)
By Diagnosis (Blood tests, Genetic tests, Nerve conduction study, Magnetic resonance imaging (MRI), Psychological and cognitive tests, Others)
By Treatment Type (Pharmacotherapy, Gene Therapy (AGT-183, GSK-2696274, Others), Enzyme replacement or enhancement therapy, Substrate reduction therapy, Others)
By End-User (Hospital, Clinics, Diagnostic Centers, Others)
Regional Analysis for Metachromatic leukodystrophy Treatment Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=metachromatic-leukodystrophy-treatment-market?sg
Major Key Players: ArmaGen, Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc, Magenta Therapeutics, Recursion Pharmaceuticals Inc. and RegenxBio Inc.
Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metachromatic leukodystrophy treatment market 2025: Industry Developments, Future Growth, Share & Industry Insights | ArmaGen, Inc., GlaxoSmithKline plc, Takeda Pharmaceutical, Orchard Therapeutics plc, Magenta Therapeutics here
News-ID: 4285228 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Biorefinery Market to Reach US$ 398.15 Billion by 2032 at 8.2% CAGR - North Amer …
The Global Biorefinery Market reached US$ 211.95 billion in 2024 and is expected to reach US$ 398.15 billion by 2032, growing at a CAGR of 8.2% during the forecast period 2025-2032. The market is expanding steadily due to rising global energy demand driven by population growth and increasing concerns over climate change caused by escalating greenhouse gas emissions.
Market growth is supported by the growing need for sustainable and renewable alternatives…
Refrigerated Warehousing Market is growing at a CAGR of 17.9%, led by Asia-Pacif …
The global Refrigerated warehousing market size was valued at USD 85.35 billion in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 17.9% from 2023 to 2030. The market is driven by factors such as growing consumption of frozen foods and changing consumer preferences. Moreover, the growing adoption of automation in refrigerated warehouses is boosting market growth. A refrigerated warehouse is a space or building…
Fuel Cell for Aircraft Market Poised for Rapid Growth at 24.5% CAGR Through 2031 …
The Global Fuel Cell for Aircraft Market reached US$ 178.3 million in 2022 and is expected to reach US$ 1,097.0 million by 2031, growing at a CAGR of 24.5% during the forecast period 2024-2031. The market is witnessing rapid growth as the aviation industry increasingly focuses on reducing carbon emissions and adopting cleaner propulsion technologies.
Market expansion is driven by rising investments in sustainable aviation, advancements in hydrogen fuel cell technology,…
Care Management Solutions Market Set for Strong Growth to USD 22.1 Billion by 20 …
The Global Care Management Solutions Market reached USD 12.6 billion in 2022 and is expected to reach USD 22.1 billion by 2030, growing at a strong CAGR of 11.5% during 2024-2031.
Market growth is driven by increasing prevalence of chronic diseases, rising demand for coordinated and value-based healthcare, and growing adoption of digital health platforms. Additionally, advancements in healthcare IT, expanding use of population health management tools, and the push to…
More Releases for Metachromatic
Metachromatic Leukodystrophy Market to Reach USD 182.6 Million by 2034
Pune, India - December 2025 - The global Metachromatic Leukodystrophy (MLD) Market, valued at USD 62.4 million in 2024, is projected to reach USD 182.6 million by 2034, growing at a powerful 11.2% CAGR (2025-2034), according to Exactitude Consultancy. Rapid advancements in gene therapy, improved diagnostic capabilities, and growing awareness of rare neurodegenerative disorders are accelerating market growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72057
Market Summary
The Metachromatic Leukodystrophy Market…
Metachromatic Leukodystrophy (MLD) market is expected to reach USD 1.1 billion b …
Metachromatic Leukodystrophy (MLD) is a rare, inherited lysosomal storage disorder caused by a deficiency in the enzyme arylsulfatase A (ARSA), leading to toxic accumulation of sulfatides in the nervous system. This results in progressive demyelination, neurodegeneration, and severe physical and cognitive decline. MLD manifests in late-infantile, juvenile, and adult-onset forms, with the late-infantile subtype being the most aggressive and fatal without intervention.
Download Full PDF Sample Copy of Market Report @…
Metachromatic Leukodystrophy Treatment Market to Exceed USD 479.51 Million by 20 …
Metachromatic leukodystrophy (MLD) is a rare but devastating genetic disorder that primarily affects children and leads to progressive deterioration of the nervous system. Historically, the absence of effective treatment options and the rapid progression of the disease left families with few avenues for intervention. However, recent breakthroughs in gene therapy, enzyme replacement therapy (ERT), and early diagnostic screening have changed the landscape dramatically.
Download Full PDF Sample Copy of Market Report…
Metachromatic Leukodystrophy Pipeline Insight 2025: Advancing Gene Therapies and …
DelveInsight's "Metachromatic Leukodystrophy - Pipeline Insight, 2025" report delivers a detailed overview of the therapeutic development landscape targeting this rare, inherited lysosomal storage disorder caused by arylsulfatase A (ARSA) deficiency. Characterized by progressive demyelination affecting the central and peripheral nervous systems, Metachromatic Leukodystrophy (MLD) often leads to severe motor and cognitive decline, with limited treatment options available until recently.
In 2025, the MLD pipeline is dominated by advanced gene therapies and…
Metachromatic Leukodystrophy Treatment Market is expected to show growth from 20 …
Metachromatic Leukodystrophy Treatment Market was valued at USD 3.53 Bn. in 2023 and is expected to reach USD 7.06 Bn. by 2030, at a CAGR of 10.4% over the forecast period (2024-2030).
Metachromatic Leukodystrophy Treatment Market Overview
Metachromatic leukodystrophy (MLD) is a rare genetic disorder caused by a deficiency of the enzyme arylsulfatase A, which is vital for maintaining myelin, the protective layer around nerve fibers. Without this enzyme, myelin deteriorates,…
Metachromatic Leukodystrophy Pipeline, FDA Approvals, Clinical Trials Developmen …
DelveInsight's, "Metachromatic Leukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Metachromatic Leukodystrophy pipeline landscape. It covers the Metachromatic Leukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metachromatic Leukodystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Metachromatic Leukodystrophy…
